Ionis Pharmaceuticals, Inc. is on track for back-to-back drug launches after announcing positive Phase III data on its ligand-conjugated anti-sense (LICA) medicine donidalorsen as a prophylactic treatment for hereditary angioedema (HAE), which Ionis could submit for US Food and Drug Administration approval soon after it submits olezarsen for familial chylomicronemia syndrome (FCS).
The company announced positive data from the Phase III OASIS-HAE study of donidalorsen on 22 January and said it is...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?